Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.
Japanese journal of clinical oncology（2023）
摘要
The efficacy and safety results in the Japanese subgroup were consistent with the overall population of CheckMate 274.
更多查看译文
关键词
Japanese,adjuvant chemotherapy,carcinoma,nivolumab,urinary bladder neoplasms
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要